BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8622033)

  • 1. Tumor size and prognosis in aggressively treated osteosarcoma.
    Bieling P; Rehan N; Winkler P; Helmke K; Maas R; Fuchs N; Bielack S; Heise U; Jurgens H; Treuner J; Romanowski R; Exner U; Kotz R; Winkler K
    J Clin Oncol; 1996 Mar; 14(3):848-58. PubMed ID: 8622033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
    Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
    Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma.
    Lee JA; Kim MS; Kim DH; Lim JS; Yoo JY; Koh JS; Lee SY; Jeon DG; Park KD
    Pediatr Blood Cancer; 2008 Feb; 50(2):195-200. PubMed ID: 18061933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
    Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
    Serra M; Scotlandi K; Reverter-Branchat G; Ferrari S; Manara MC; Benini S; Incaprera M; Bertoni F; Mercuri M; Briccoli A; Bacci G; Picci P
    J Clin Oncol; 2003 Feb; 21(3):536-42. PubMed ID: 12560446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
    Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
    Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
    Jeon DG; Kong CB; Cho WH; Song WS; Cho SH; Choi SW; Lee SY
    J Surg Oncol; 2014 Mar; 109(3):275-9. PubMed ID: 24243222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
    Kempf-Bielack B; Bielack SS; Jürgens H; Branscheid D; Berdel WE; Exner GU; Göbel U; Helmke K; Jundt G; Kabisch H; Kevric M; Klingebiel T; Kotz R; Maas R; Schwarz R; Semik M; Treuner J; Zoubek A; Winkler K
    J Clin Oncol; 2005 Jan; 23(3):559-68. PubMed ID: 15659502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new relative tumor sizing method in epi-metaphyseal osteosarcoma.
    Kim SH; Shin KH; Park EH; Cho YJ; Park BK; Suh JS; Yang WI
    BMC Cancer; 2015 Apr; 15():284. PubMed ID: 25885468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant chemotherapy of osteosarcoma. Results of the cooperative studies COSS-80 and COSS-82 after 7 and 5 years].
    Bielack S; Beck J; Delling G; Gerein V; Grümayer R; Hiddemann W; Jobke A; Jürgens H; Kornhuber G; Kotz R
    Klin Padiatr; 1989; 201(4):275-84. PubMed ID: 2674532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors for 72 patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy].
    Liu J; Guo W; Yang RL; Tang XD; Yang Y
    Zhonghua Wai Ke Za Zhi; 2008 Aug; 46(15):1166-70. PubMed ID: 19094683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy-induced changes in osteosarcoma after neoadjuvant chemotherapy (COSS 86 Therapy Study). Correlation between morphologic findings and clinical follow-up].
    Werner M; Fuchs N; Salzer-Kuntschik M; Winkler K; Delling G
    Pathologe; 1996 Jan; 17(1):35-43. PubMed ID: 8685094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Goal and results of the COSS study].
    Flege S; Bielack S
    Handchir Mikrochir Plast Chir; 2004 Oct; 36(5):282-8. PubMed ID: 15503258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
    Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
    J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pelvis and extremity osteosarcoma with similar tumor volume have an equivalent survival.
    Song WS; Cho WH; Jeon DG; Kong CB; Kim MS; Lee JA; Eid AS; Kim JD; Lee SY
    J Surg Oncol; 2010 Jun; 101(7):611-7. PubMed ID: 20461769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma.
    Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
    Ann Oncol; 2009 May; 20(5):955-60. PubMed ID: 19153123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.
    Provisor AJ; Ettinger LJ; Nachman JB; Krailo MD; Makley JT; Yunis EJ; Huvos AG; Betcher DL; Baum ES; Kisker CT; Miser JS
    J Clin Oncol; 1997 Jan; 15(1):76-84. PubMed ID: 8996127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.